Class of 2011 Abstract / OBJECTIVES: The objective of this study was to compare patient clinical outcomes, vascular access line administration complications, and piperacillin-tazobactam costs before and after implementation of an extended infusion piperacillin-tazobactam protocol in adult patients at an academic medical center.
METHODS: In this IRB-approved retrospective project, the effect of the implementation of a piperacillin- tazobactam extended infusion protocol at a tertiary care, academic medical center was accessed. The use of piperacillin-tazobactam was accessed during 3 one-month time periods in 2010: Time Period 1 (pre-education and implementation of protocol), Time Period 2 (post-education of pharmacists and infectious disease physicians), and Time Period 3 (post-education of healthcare professionals and implementation of extended-infusion piperacillin- tazobactam protocol). Patients were excluded if piperacillin-tazobactam therapy was prescribed for less than 72 hours. Data collected in each one-month period included demographic data, culture results, number of piperacillin-tazobactam grams prescribed per day, percentage of patients who received extended-infusion piperacillin-tazobactam, other antimicrobial therapy prescribed, medications prescribed with intravenous incompatibilities with piperacillin-tazobactam, number of intravenous line lumens before and after start of piperacillin-tazobactam therapy, length of stay, and all-cause 30 day mortality.
RESULTS: During a three step process, the use of extended infusion piperacillin-tazobactam was implemented at an academic medical center after administration approval, education of healthcare professionals, and development of an electronic piperacillin-tazobactam order set. Use of extended-infusion piperacillin-tazobactam protocol significantly decreased the average daily piperacillin-tazobactam dose per patient.
CONCLUSION: Implementation of extended-infusion piperacillin-tazobactam protocol for adult patients did significantly decrease the average daily dose of piperacillin-tazobactam per patient (reduced drug cost) but increased vascular access requirements.
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/623574 |
| Date | January 2011 |
| Creators | Radosevich, John, Brunelle, Adam, DiPede, Michael |
| Contributors | Matthias, Kathryn, College of Pharmacy, The University of Arizona |
| Publisher | The University of Arizona. |
| Source Sets | University of Arizona |
| Language | en_US |
| Detected Language | English |
| Type | text, Electronic Report |
| Rights | Copyright © is held by the author. |
Page generated in 0.0023 seconds